Cargando…
Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells
BACKGROUND: The co-stimulatory inhibitor of the CD28-CD80/86-pathway, belatacept, allows calcineurin-inhibitor-free immunosuppression in kidney transplantation. However, aggressive T-cell mediated allogeneic responses have been observed in belatacept-treated patients, which could be explained by eff...
Autores principales: | de Graav, Gretchen N., Hesselink, Dennis A., Dieterich, Marjolein, Kraaijeveld, Rens, Weimar, Willem, Baan, Carla C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769294/ https://www.ncbi.nlm.nih.gov/pubmed/26919152 http://dx.doi.org/10.1371/journal.pone.0148604 |
Ejemplares similares
-
Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: de Graav, Gretchen N., et al.
Publicado: (2017) -
Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial
por: Kannegieter, Nynke M., et al.
Publicado: (2017) -
Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Baan, Carla C., et al.
Publicado: (2018) -
Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients
por: Kannegieter, Nynke M., et al.
Publicado: (2018) -
Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)